1169 AZD5863: a specific, potent, affinity-optimized claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing

• Rakesh Kumar,
• Yun He,
• Simon Dovedi,
• Mark Cobbold,
• Kristen Pollizzi,
• Saso Cemerski,
• Scott Hammond,
• Marina Natoli,
• Yiping Rong,
• Jonathan Fitzgerald,
• Mary McFarlane,
• Kathy Mulgrew,
• Miguel Gaspar,
• Christopher Lloyd,
• Douglas C Palmer,
• Maria AS Broggi,
• Laure Castan,
• Sharif Rahmy,
• Cathryn Kelton,
• Martin Korade,
• Oisin Huhn,
• D Gareth Rees,
• Anna Sigurdardottir,
• Benjamin Ridgway,
• Kathryn Ball,
• Fred Arce Vargas,
• Natalia Ceaicovscaia,
• Gayle Pouliot,
• Philip Szekeres

Affiliations

Rakesh Kumar

2AstraZeneca, Gaithersburg, MD, USA

Yun He

School of Medicine, Imperial College School of Medicine, London, UK

Simon Dovedi

1Astrazeneca, Cambridge, UK

Mark Cobbold

1AstraZeneca, Gaithersburg, MD, USA

Kristen Pollizzi

Aff6 grid.418152.bDiscovery Sciences, Oncology R&D, AstraZeneca Gaithersburg MD USA

Saso Cemerski

Scott Hammond

Aff2 grid.418152.bMedImmune Gaithersburg MD USA

Marina Natoli

1Astrazeneca, Cambridge, UK

Yiping Rong

Harbour Biomed, Shanghai, China

Jonathan Fitzgerald

3Repertoire Immune Medicines, Cambridge, MA, USA

Mary McFarlane

Division of STD Prevention, CDC, Atlanta, Georgia, USA

Kathy Mulgrew

AstraZeneca, Gaithersburg, Maryland, USA

Miguel Gaspar

F-star Therapeutics Inc, Cambridge, UK

Christopher Lloyd

1Astrazeneca, Cambridge, UK

Douglas C Palmer

3AstraZeneca, Gaithersburg, MD, USA

Maria AS Broggi

1AstraZeneca, Gaithersburg, MD, USA

Laure Castan

1Astrazeneca, Cambridge, UK

Sharif Rahmy

Cathryn Kelton

Martin Korade

Oisin Huhn

1Astrazeneca, Cambridge, UK

D Gareth Rees

1Astrazeneca, Cambridge, UK

Anna Sigurdardottir

1Astrazeneca, Cambridge, UK

Benjamin Ridgway

Kathryn Ball

1Astrazeneca, Cambridge, UK

Fred Arce Vargas

1Astrazeneca, Cambridge, UK

Natalia Ceaicovscaia

Gayle Pouliot

5AstraZeneca, Waltham, MA, USA

Philip Szekeres

1Astrazeneca, Cambridge, UK